Wondermed is a company.
Key people at Wondermed.
Wondermed was founded by Jose Muñoz Aycart (Co-Founder / Managing Director).
Wondermed is a telemedicine platform delivering at-home, low-dose ketamine therapy combined with AI-guided protocols for treating anxiety, depression, and related mental health conditions.[1][2][3] It serves adults seeking alternatives to daily pharmaceuticals like SSRIs or opioids, offering WonderFlow—a structured program blending clinician-supervised ketamine lozenges, neuroscience-based supplements, personalized AI care plans, behavioral therapy, and progress tracking for faster symptom relief (89% efficacy in studies vs. <40% for SSRIs) at $399/month.[3] The company solves treatment-resistant mental health issues by promoting neuroplasticity and long-term resilience through convenient, affordable, at-home care, with services available in multiple states and backed by over $5.3M in seed funding as of 2022.[1]
Founded by CEO Ryan Magnussen, Wondermed emerged from his vision to revolutionize mental health via psychedelic medicine, neuroscience, and innovative therapies like low-dose at-home ketamine.[1] Magnussen, a champion for psychedelics and self-optimization, turned the idea into reality by raising a seed round exceeding $5.3M from investors including Aubrey Marcus, James Foster (CEO of Charles River Laboratories), SDG Impact Fund, Phyto Partners, Tejo Ventures, and Ambria Capital.[1] Early traction included scaling at-home solutions and expanding to 11 states by 2022, with goals to reach 19 states and close seed funding at $7M that year, while building a network of ketamine-experienced professionals and pioneering AI research.[1]
Wondermed rides the surge in psychedelic medicine and telehealth for mental health, capitalizing on ketamine's FDA recognition for depression and growing acceptance of at-home therapies post-COVID.[1][2][5] Timing aligns with market shifts: rising demand for non-pharma alternatives amid SSRI limitations (<40% efficacy), opioid crises (75% overdose deaths involve them), and AI integration in healthcare for personalized care.[3] It influences the ecosystem by normalizing psychedelics through research, clinician networks, and accessible protocols, potentially accelerating adoption in a $200B+ mental health market while bridging neuroscience startups with investors like Phyto Partners.[1][3]
Wondermed is poised to expand WonderFlow nationally, deepen AI research (e.g., predictive healing models), and launch Wonder Relief for pain management, targeting broader psychedelic protocols amid regulatory tailwinds.[1][3] Trends like AI-driven telehealth, neuroplasticity-focused therapies, and psychedelic decriminalization will propel growth, evolving its role from niche ketamine provider to comprehensive precision mental health platform. This positions Wondermed to transform accessible healing, fulfilling Magnussen's vision of elevating collective consciousness through innovative, patient-empowered care.[1]
Key people at Wondermed.
Wondermed was founded by Jose Muñoz Aycart (Co-Founder / Managing Director).
